Bicuspid Aortic Valve Stenosis: Favorable Early Outcomes With a Next-Generation Transcatheter Heart Valve in a Multicenter Study.

The presence of a bicuspid valve has been considered as a relative contraindication for transcatheter aortic valve implantation (TAVI). This a multicentre retrospective study of 51 patients with bicuspid aortic stenosis who had undergone TAVI using a next-generation transcatheter heart valve (Edwards SAPIEN 3). 30- day mortality was 3,9%. There were no cases of valve embolization, need for a second prosthesis or annular rupture. Post implantation ballooning was required in 7.8% of the patients. None of the patients had more than mild aortic regurgitation (AR). Mild AR was detected in 37% of the cases. Pacemaker implantation was required in 23,5% of the cases. In this group of patients with bicuspid aortic stenosis, implantation of a new-generation device was associated with minimal paravalvular regurgitation and good clinical outcomes, but a higher than usual need for pacemaker implantation.